<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HB5A53430B737450996B9E94FDA89910E" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>111 HR 6833 IH: Affordable Insulin Now Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-02-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6833</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220225">February 25, 2022</action-date><action-desc><sponsor name-id="C001119">Ms. Craig</sponsor> (for herself, <cosponsor name-id="K000380">Mr. Kildee</cosponsor>, and <cosponsor name-id="M001208">Mrs. McBath</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committees on <committee-name committee-id="HWM00">Ways and Means</committee-name>, and <committee-name committee-id="HED00">Education and Labor</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XXVII of the Public Health Service Act, the Internal Revenue Code of 1986, and the Employee Retirement Income Security Act of 1974 to establish requirements with respect to cost-sharing for certain insulin products, and for other purposes.</official-title></form><legis-body id="HFCDEDDD7F421484AA420A8717348D651" style="OLC"><section id="H431835E22A214DCAA3980749BB5B2A9C" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Affordable Insulin Now Act</short-title></quote>.</text></section><section id="HE6AD5AE200024F52815D8FDE7BDB264E"><enum>2.</enum><header>Requirements with respect to cost-sharing for insulin products</header><subsection id="H5A60754BE1044F6F98019900FF3EE0DE"><enum>(a)</enum><header>PHSA</header><text display-inline="yes-display-inline">Part D of title XXVII of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-111">42 U.S.C. 300gg–111 et seq.</external-xref>) is amended by adding at the end the following new section:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H714CB185DD6141A6A2072BB6A767E968"><section id="H29A4EC55C57E4B0F86254DEA4462CCB5"><enum>2799A–11.</enum><header>Requirements with respect to cost-sharing for certain insulin products</header><subsection id="H13C1CE7982DF4084BB44665BC8642971"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For plan years beginning on or after January 1, 2023, a group health plan or health insurance issuer offering group or individual health insurance coverage shall provide coverage of selected insulin products, and with respect to such products, shall not—</text><paragraph id="H5CCE80A2CF0B4796BD0017F53D9E710F"><enum>(1)</enum><text>apply any deductible; or</text></paragraph><paragraph id="H6501EB3FFB884485A80A4D2DD8B052AC"><enum>(2)</enum><text>impose any cost-sharing in excess of the lesser of, per 30-day supply—</text><subparagraph id="HC0E41952FCD04474B3B2CF190BC8D6D5"><enum>(A)</enum><text>$35; or</text></subparagraph><subparagraph id="H71F8C628492A445EBA00E0FF10AC4DC8"><enum>(B)</enum><text>the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan or coverage, including price concessions received by or on behalf of third-party entities providing services to the plan or coverage, such as pharmacy benefit management services.</text></subparagraph></paragraph></subsection><subsection id="H277F0E6812C842C1879EDACA9E8D9125"><enum>(b)</enum><header>Definitions</header><text>In this section:</text><paragraph id="H7AAAAFAD2AFB4BD9907EE55BAE8C22A5"><enum>(1)</enum><header>Selected insulin products</header><text>The term <term>selected insulin products</term> means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan or health insurance issuer.</text></paragraph><paragraph id="HECBD3923C23F41C4835BB3DF9711D6F3"><enum>(2)</enum><header>Insulin defined</header><text>The term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 and continues to be marketed pursuant to such licensure. </text></paragraph></subsection><subsection id="H81878515BF984BD0BF7E76DBCCD2A2BD"><enum>(c)</enum><header>Out-of-Network providers</header><text>Nothing in this section requires a plan or issuer that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan or issuer that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.</text></subsection><subsection id="H919E398C5823445E82E7A7CCBCDB7CE8"><enum>(d)</enum><header>Rule of construction</header><text>Subsection (a) shall not be construed to require coverage of, or prevent a group health plan or health insurance coverage from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.</text></subsection><subsection commented="no" id="HBFB18D15ABDB4D1D93465CFCECECA25A"><enum>(e)</enum><header>Application of cost-Sharing towards deductibles and out-of-Pocket maximums</header><text>Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan or coverage.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H4E99A27D3D4247B2AA406CF18E335274"><enum>(b)</enum><header>IRC</header><paragraph id="H742AAA1975A145D6841391A5B959A4B6"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subchapter B of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/100">chapter 100</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H62E9484ECE704A6D8904963791D53BC9"><section id="HC1067A8F9D9C4C0FA2203DECB8B73437"><enum>9826.</enum><header>Requirements with respect to cost-sharing for certain insulin products</header><subsection id="HBA6FF7B7352C4A8FAA2C2680EB31B52A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For plan years beginning on or after January 1, 2023, a group health plan shall provide coverage of selected insulin products, and with respect to such products, shall not—</text><paragraph id="H304A7A6A476E4AC1A3D3B4841EF9A564"><enum>(1)</enum><text>apply any deductible; or</text></paragraph><paragraph id="HB89BE44B308F4C32889C311283D5A035"><enum>(2)</enum><text>impose any cost-sharing in excess of the lesser of, per 30-day supply—</text><subparagraph id="HEF1E05F1FFD44758ACDB029EF34B5724"><enum>(A)</enum><text>$35; or</text></subparagraph><subparagraph id="H138F82DE74D44BD5BA41670D43F662E9"><enum>(B)</enum><text>the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan, including price concessions received by or on behalf of third-party entities providing services to the plan, such as pharmacy benefit management services.</text></subparagraph></paragraph></subsection><subsection id="HB6E1C916BDB441C0B54670E974D71B14"><enum>(b)</enum><header>Definitions</header><text>In this section:</text><paragraph id="HEEBCADB46DD34FAA998B30122BB78F0E"><enum>(1)</enum><header>Selected insulin products</header><text>The term <term>selected insulin products</term> means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan.</text></paragraph><paragraph id="H413F0534DA364D9B99A78D9174E38824"><enum>(2)</enum><header>Insulin defined</header><text>The term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) and continues to be marketed pursuant to such licensure. </text></paragraph></subsection><subsection id="H05A011E27AD6433EBFBC98BAA6D0EE44"><enum>(c)</enum><header>Out-of-Network providers</header><text>Nothing in this section requires a plan that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.</text></subsection><subsection id="HBAAF86F32963466EB78DE86821B90E4D"><enum>(d)</enum><header>Rule of construction</header><text>Subsection (a) shall not be construed to require coverage of, or prevent a group health plan from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.</text></subsection><subsection id="H407D393B01BA41CDB69ED1AD87132E24" commented="no"><enum>(e)</enum><header>Application of cost-Sharing towards deductibles and out-of-Pocket maximums</header><text>Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H5C84E6776A4A4422BF20494538172251"><enum>(2)</enum><header>Clerical amendment</header><text>The table of sections for subchapter B of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/100">chapter 100</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:</text><quoted-block display-inline="no-display-inline" id="H981C031AE6CD47FAAC1CAFDAA40002A7" style="OLC"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 9826. Requirements with respect to cost-sharing for certain insulin products.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H686C01D3E8A74AC78D35E384A759208E" display-inline="no-display-inline"><enum>(c)</enum><header>ERISA</header><paragraph id="H5633B13D06894AB8AFA18862B182F818"><enum>(1)</enum><header>In general</header><text>Subpart B of part 7 of subtitle B of title I of the Employee Retirement Income Security Act of 1974 (<external-xref legal-doc="usc" parsable-cite="usc/29/1185">29 U.S.C. 1185 et seq.</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HA25609E9936B4B83BFD989AB39510E0E"><section id="HE3CBC92557B74C11B1712C7685EFFCFA"><enum>726.</enum><header>Requirements with respect to cost-sharing for certain insulin products</header><subsection id="H1498B1FEE3AF4AE9B0318A7F0ABA44B0"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">For plan years beginning on or after January 1, 2023, a group health plan or health insurance issuer offering group health insurance coverage shall provide coverage of selected insulin products, and with respect to such products, shall not—</text><paragraph id="H5F4CB5B18C5041A48348B644B29801F3"><enum>(1)</enum><text>apply any deductible; or</text></paragraph><paragraph id="H44FFE54E9C0E4010ADB0D9A7966D5FDA"><enum>(2)</enum><text>impose any cost-sharing in excess of the lesser of, per 30-day supply—</text><subparagraph id="HA42B740A59774F698C3B639253C5E22E"><enum>(A)</enum><text>$35; or</text></subparagraph><subparagraph id="HA4830EA540DC43108EC411F02AA30268"><enum>(B)</enum><text>the amount equal to 25 percent of the negotiated price of the selected insulin product net of all price concessions received by or on behalf of the plan or coverage, including price concessions received by or on behalf of third-party entities providing services to the plan or coverage, such as pharmacy benefit management services.</text></subparagraph></paragraph></subsection><subsection id="H1D4EA0860E8C420FAE75D11E04079287"><enum>(b)</enum><header>Definitions</header><text>In this section:</text><paragraph id="H8FE60E31D9D44BB0893A3AED94BC7397"><enum>(1)</enum><header>Selected insulin products</header><text>The term <term>selected insulin products</term> means at least one of each dosage form (such as vial, pump, or inhaler dosage forms) of each different type (such as rapid-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and premixed) of insulin (as defined below), when available, as selected by the group health plan or health insurance issuer.</text></paragraph><paragraph id="HFD7431A226F5462E852F4D3FEFA9A20F"><enum>(2)</enum><header>Insulin defined</header><text>The term <term>insulin</term> means insulin that is licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) and continues to be marketed under such section, including any insulin product that has been deemed to be licensed under section 351(a) of such Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 (<external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) and continues to be marketed pursuant to such licensure. </text></paragraph></subsection><subsection id="H7F3720B4DEC74520B41C31068EC6F321"><enum>(c)</enum><header>Out-of-Network providers</header><text>Nothing in this section requires a plan or issuer that has a network of providers to provide benefits for selected insulin products described in this section that are delivered by an out-of-network provider, or precludes a plan or issuer that has a network of providers from imposing higher cost-sharing than the levels specified in subsection (a) for selected insulin products described in this section that are delivered by an out-of-network provider.</text></subsection><subsection id="HCFB28D5933F142E7B3483AC8050EB6E6"><enum>(d)</enum><header>Rule of construction</header><text>Subsection (a) shall not be construed to require coverage of, or prevent a group health plan or health insurance coverage from imposing cost-sharing other than the levels specified in subsection (a) on, insulin products that are not selected insulin products, to the extent that such coverage is not otherwise required and such cost-sharing is otherwise permitted under Federal and applicable State law.</text></subsection><subsection commented="no" id="H58F5D45A64A34058A2FADDE0B98D58E5"><enum>(e)</enum><header>Application of cost-Sharing towards deductibles and out-of-Pocket maximums</header><text>Any cost-sharing payments made pursuant to subsection (a)(2) shall be counted toward any deductible or out-of-pocket maximum that applies under the plan or coverage.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HD45EEF701E3341978B2539FF325C47DE"><enum>(2)</enum><header>Clerical amendment</header><text>The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 (<external-xref legal-doc="usc" parsable-cite="usc/29/1001">29 U.S.C. 1001 et seq.</external-xref>) is amended by inserting after the item relating to section 725 the following:</text><quoted-block display-inline="no-display-inline" id="H8B328629B6AA4655970D6C739B7386C7" style="OLC"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 726. Requirements with respect to cost-sharing for certain insulin products.</toc-entry></toc><after-quoted-block>. </after-quoted-block></quoted-block></paragraph></subsection><subsection id="H220C9F69207C487B84DC09414F5B4AB9"><enum>(d)</enum><header>No effect on other cost-Sharing</header><text>Section 1302(d)(2) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18022">42 U.S.C. 18022(d)(2)</external-xref>) is amended by adding at the end the following new subparagraph:</text><quoted-block style="OLC" id="HFE66A1B87B5F4F5299D1016CB674BC67" display-inline="no-display-inline"><subparagraph id="HBBA3924BCF4446D68547771762A01722"><enum>(D)</enum><header>Special rule relating to insulin coverage</header><text display-inline="yes-display-inline">The exemption of coverage of selected insulin products (as defined in section 2799A–11(b) of the Public Health Service Act) from the application of any deductible pursuant to section 2799A–11(a)(1) of such Act, section 726(a)(1) of the Employee Retirement Income Security Act of 1974, or <external-xref legal-doc="usc" parsable-cite="usc/26/9826">section 9826(a)(1)</external-xref> of the Internal Revenue Code of 1986 shall not be considered when determining the actuarial value of a qualified health plan under this subsection.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HE97C2EE2C31B41B992B9BB474B0F7589"><enum>(e)</enum><header>Coverage of certain insulin products under catastrophic plans</header><text>Section 1302(e) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18022">42 U.S.C. 18022(e)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HAAC08531C1C54A6EA3B6EDA2870BA76B"><paragraph id="H2075EC5C93A749B98C6A9BDB5C8995F5"><enum>(4)</enum><header>Coverage of certain insulin products</header><subparagraph id="H549C1328163740BE938F0DDA397AEE37"><enum>(A)</enum><header>In general</header><text>Notwithstanding paragraph (1)(B)(i), a health plan described in paragraph (1) shall provide coverage of selected insulin products, in accordance with section 2799A–11 of the Public Health Service Act, for a plan year before an enrolled individual has incurred cost-sharing expenses in an amount equal to the annual limitation in effect under subsection (c)(1) for the plan year.</text></subparagraph><subparagraph id="H95F638B28F2447E093D88C2769D18990"><enum>(B)</enum><header>Terminology</header><text>For purposes of subparagraph (A)—</text><clause id="H6A450C35E00E46EBB101D62E22D85DDA"><enum>(i)</enum><text>the term <term>selected insulin products</term> has the meaning given such term in section 2799A–11(b) of the Public Health Service Act; and</text></clause><clause id="HE44EECF0B0E34A3EAE39F89B6F351A85"><enum>(ii)</enum><text>the requirements of section 2799A–11 of such Act shall be applied by deeming each reference in such section to <quote>individual health insurance coverage</quote> to be a reference to a plan described in paragraph (1). </text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="HEFC3D0916D53471D8964CC4708B3E187" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>3.</enum><header>Appropriate cost-sharing for certain insulin products under Medicare part D</header><subsection id="H918AC763223249C996CAE8CC82EA1213" commented="no"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1860D–2 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102</external-xref>) is amended—</text><paragraph id="HDD27C533185F4194950F9D14C9710F68" commented="no"><enum>(1)</enum><text>in subsection (b)—</text><subparagraph id="HD340C338E64E4631BEE167B1BDD03FB0" commented="no"><enum>(A)</enum><text>in paragraph (1)(A), by striking <quote>The coverage</quote> and inserting <quote>Subject to paragraph (8), the coverage</quote>;</text></subparagraph><subparagraph id="HA961AB8B6EB24477A62560EEFC602352" commented="no"><enum>(B)</enum><text>in paragraph (2)(A), by striking <quote>and (D)</quote> and inserting <quote>and (D) and paragraph (8)</quote>;</text></subparagraph><subparagraph id="HA829788559194A32AB5F85E199826159" commented="no"><enum>(C)</enum><text>in paragraph (3)(A), by striking <quote>and (4)</quote> and inserting <quote>(4), and (8)</quote>;</text></subparagraph><subparagraph id="HB5AD585573AB49C1A6153811D6E07248" commented="no"><enum>(D)</enum><text>in paragraph (4)(A)(i), by striking <quote>The coverage</quote> and inserting <quote>Subject to paragraph (8), the coverage</quote>; and</text></subparagraph><subparagraph id="H129B172F8D2B488FAAA457BEEC32652C" commented="no"><enum>(E)</enum><text>by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H7D3E6E884F2D425287FE68A8DD8D47F1"><paragraph id="H031816C5C5904B5BAA8EE3D754BB1DC8" commented="no"><enum>(8)</enum><header>Treatment of cost-sharing for certain insulin products</header><subparagraph id="H0E60C833B9F74297B801646D27194DE2" commented="no"><enum>(A)</enum><header>In general</header><text>For plan years beginning on or after January 1, 2023, the following shall apply with respect to insulin products (as defined in subparagraph (B)):</text><clause id="H4A326C4358FE4F4CA926A1CA0C407278" commented="no"><enum>(i)</enum><header>No application of deductible</header><text>The deductible under paragraph (1) shall not apply with respect to such insulin products.</text></clause><clause id="H96F4B8BFF4EA44BFBFE30E080E894C99" commented="no"><enum>(ii)</enum><header>Application of cost-sharing</header><subclause id="H927C8D3BF3CA4920BDFDCFD3B7F3E1A3" commented="no"><enum>(I)</enum><header>Plan year 2023</header><text>For plan year 2023, the coverage provides benefits for such insulin products, regardless of whether an individual has reached the initial coverage limit under paragraph (3) or the out-of-pocket threshold under paragraph (4), with cost-sharing that is equal to the applicable copayment amount.</text></subclause><subclause id="H681432D72DF740498624CC4BCB43B179" commented="no"><enum>(II)</enum><header>Plan year 2024 and subsequent plan years</header><text>For plan year 2024 and subsequent plan years, the coverage provides benefits for such insulin products, prior to an individual reaching the out-of-pocket threshold under paragraph (4), with cost-sharing that is equal to the applicable copayment amount.</text></subclause><subclause id="H056086BA92A34D568B231A6D4DA38FE0" commented="no"><enum>(III)</enum><header>Applicable copayment amount</header><text>For purposes of this clause, the term <quote>applicable copayment amount</quote> means, with respect to an insulin product under a prescription drug plan or an MA–PD plan, an amount that is not more than $35.</text></subclause></clause></subparagraph><subparagraph id="H681384D34CC2428DA64358F9376F92D6" commented="no"><enum>(B)</enum><header>Insulin product</header><text display-inline="yes-display-inline">For purposes of this paragraph, the term <quote>insulin product</quote> means an insulin product that is approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act and marketed pursuant to such approval or licensure, including any insulin product that has been deemed to be licensed under section 351 of the Public Health Service Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 and marketed pursuant to such section.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HDC23696BBFE24EDFAD6FBADA9C2B316E" commented="no"><enum>(2)</enum><text>in subsection (c), by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H6D4ED52D7D494692A60C538A8EC0FBD8"><paragraph id="H8FEAD0808E1B4587B820524E3B6287C9" commented="no"><enum>(4)</enum><header>Treatment of cost-sharing for insulin products</header><text>The coverage is provided in accordance with subsection (b)(8).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H0EFE605EB3C24B649C85B8931A2BC8E3" commented="no"><enum>(b)</enum><header>Conforming amendments to cost-Sharing for low-Income individuals</header><text>Section 1860D–14(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-114">42 U.S.C. 1395w–114(a)</external-xref>) is amended—</text><paragraph id="H65ED92F59A774C09B105E31216CF3800" commented="no"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph id="H9DADBFFD905C4CB4BDF2874DAEE54E55" commented="no"><enum>(A)</enum><text>in subparagraph (D)(iii), by adding at the end the following new sentence: <quote>For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to an insulin product (as defined in section 1860D–2(b)(8)(B)) furnished to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.</quote>; and</text></subparagraph><subparagraph id="HFDF0D961040D4CA3AFA955CE0969EBAE" commented="no"><enum>(B)</enum><text>in subparagraph (E), by inserting the following before the period at the end <quote>or under section 1860D–2(b)(8) in the case of an insulin product (as defined in subparagraph (B) of such section)</quote>; and</text></subparagraph></paragraph><paragraph id="H8A14C851DF2B4A9E9B66F73EC49B24DA" commented="no"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="HCA4ADF1DBF234BF6B570B47A8FB3AE40" commented="no"><enum>(A)</enum><text>in subparagraph (D), by adding at the end the following new sentence: <quote>For plan year 2023 and subsequent plan years, the amount of the coinsurance applicable under the preceding sentence to an insulin product (as defined in section 1860D–2(b)(8)(B)) furnished to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.</quote>; and</text></subparagraph><subparagraph id="H9F32A019A7714DD6BF5ED4CCE4AC041B" commented="no"><enum>(B)</enum><text>in subparagraph (E), by adding at the end the following new sentence: <quote>For plan year 2023, the amount of the copayment or coinsurance applicable under the preceding sentence to an insulin product (as defined in section 1860D–2(b)(8)(B)) furnished to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.</quote></text></subparagraph></paragraph></subsection><subsection id="HF345825BD6BF48D3B2A7FB24640F9171" commented="no"><enum>(c)</enum><header>Implementation</header><text>The Secretary shall implement this section for plan years 2023 and 2024 by program instruction or otherwise.</text></subsection></section></legis-body></bill> 

